NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 132 filers reported holding NOVOCURE LTD in Q1 2018. The put-call ratio across all filers is 0.13 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,075,025 | +348.5% | 66,565 | +1570.0% | 0.03% | +285.7% |
| Q1 2023 | $239,718 | -23.2% | 3,986 | -6.4% | 0.01% | -22.2% |
| Q4 2022 | $312,324 | -44.9% | 4,258 | -37.7% | 0.01% | -66.7% |
| Q1 2022 | $567,000 | -74.7% | 6,840 | -77.1% | 0.03% | -80.4% |
| Q4 2021 | $2,241,000 | +47.4% | 29,851 | +128.1% | 0.14% | +14.0% |
| Q3 2021 | $1,520,000 | -16.0% | 13,088 | -4.3% | 0.12% | -27.1% |
| Q1 2021 | $1,809,000 | +7.3% | 13,683 | -9.7% | 0.17% | +53.7% |
| Q3 2020 | $1,686,000 | +35.1% | 15,147 | -28.0% | 0.11% | +24.1% |
| Q2 2020 | $1,248,000 | +61.2% | 21,052 | +83.1% | 0.09% | +55.4% |
| Q1 2020 | $774,000 | -57.0% | 11,498 | -52.2% | 0.06% | -63.9% |
| Q3 2019 | $1,800,000 | +15.2% | 24,067 | -25.8% | 0.16% | +39.6% |
| Q1 2019 | $1,563,000 | +554.0% | 32,438 | +355.1% | 0.11% | +640.0% |
| Q4 2018 | $239,000 | -53.9% | 7,128 | -72.2% | 0.02% | -73.7% |
| Q4 2017 | $518,000 | +144.3% | 25,648 | +139.9% | 0.06% | +7.5% |
| Q3 2017 | $212,000 | – | 10,690 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Nordwand Advisors, LLC | 1,515,000 | $111,125,249 | 13.86% |
| Invus Financial Advisors, LLC | 350,884 | $25,737,341 | 13.70% |
| HARTLINE INVESTMENT CORP/ | 304,482 | $22,333,755 | 5.08% |
| GREAT POINT PARTNERS LLC | 241,000 | $17,677,350 | 3.46% |
| Tri Locum Partners LP | 72,400 | $5,311,000 | 2.15% |
| Taylor Frigon Capital Management LLC | 42,061 | $3,085,174 | 1.75% |
| HighVista Strategies LLC | 28,007 | $2,054,313 | 1.22% |
| HAP Trading, LLC | 124,500 | $10,294 | 1.05% |
| Private Harbour Investment Management & Counsel, LLC | 12,285 | $901,105 | 0.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 32,000 | $2,344,000 | 0.72% |